Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com

Emergent BioSolutions (NYSE:EBS - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Wednesday.

Several other equities analysts have also issued reports on the company. Rodman & Renshaw reissued a "buy" rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark boosted their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Up 7.4 %

Shares of NYSE:EBS traded up $0.61 during trading on Wednesday, reaching $8.88. The stock had a trading volume of 1,065,431 shares, compared to its average volume of 3,352,449. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm's fifty day moving average is $8.69 and its 200 day moving average is $8.17. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10. The stock has a market cap of $481.12 million, a price-to-earnings ratio of -2.15 and a beta of 1.57.

Institutional Investors Weigh In On Emergent BioSolutions

A number of hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in Emergent BioSolutions by 155.3% during the 1st quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company's stock valued at $414,000 after purchasing an additional 99,520 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Emergent BioSolutions by 14.7% during the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company's stock valued at $8,631,000 after buying an additional 436,911 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Emergent BioSolutions by 22.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 4,409 shares in the last quarter. Tidal Investments LLC purchased a new stake in Emergent BioSolutions in the 1st quarter valued at $34,000. Finally, Cetera Advisors LLC bought a new position in Emergent BioSolutions during the 1st quarter valued at $428,000. Institutional investors and hedge funds own 78.40% of the company's stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.